Présentation de l'entreprise
Passage Bio, Inc. operates as a genetic medicines company dedicated to developing gene therapies specifically targeting diseases within the central nervous system. The company functions within the broader healthcare sector and the specialized biotechnology industry, focusing on advanced therapeutic solutions for conditions such as frontotemporal dementia caused by progranulin deficiency. Passage Bio, Inc. currently maintains a market capitalization of $29.80M and employs a workforce of 24 individuals to advance its pipeline of functional gene therapies. The combination of a market cap near $30 million and a revenue base that is effectively zero for valuation purposes indicates that the company is in an early-stage development phase where the primary value driver is the intellectual property and potential future commercialization of its assets rather than current operational cash flow.
Santé financière
The financial statements for Passage Bio, Inc. report a net income of $-45,522,000 over the trailing twelve months, while the EBITDA stands at $-42,423,000, revealing a cost structure where operational expenses are significantly higher than the negligible gross revenue, resulting in a gross margin of 0.0%. The company generated a free cash flow of $-18,799,376, which highlights a negative financial flexibility as the organization consumes cash to fund its research and development activities rather than generating surplus liquidity. Margins across the board are non-existent, with the gross margin, operating margin, and profit margin all recorded at 0.0%, reflecting the typical economics of a pre-revenue biotechnology firm that incurs high R&D costs before achieving product sales. The balance sheet shows a cash position of $46.30M against total debt of $24.01M, resulting in a debt-to-equity ratio of 128.02, which suggests a highly leveraged capital structure relative to equity but indicates sufficient liquid assets to cover immediate obligations. Liquidity is supported by a current ratio of 2.07, indicating that the company possesses more than double the current assets necessary to settle its short-term liabilities. Return on Equity is recorded at -113.8% and Return on Assets at -32.8%, metrics that demonstrate that management is currently utilizing the company's capital base to generate negative returns due to substantial accumulated losses.
Évaluation de la valorisation
Valuation metrics for Passage Bio, Inc. present a complex picture with a trailing P/E ratio of N/A due to the lack of positive earnings and a forward P/E of -1.06, implying that the market is pricing in the expectation of future profitability turning from negative to positive. The price-to-book ratio stands at 1.58, indicating that the market values the company's equity at a premium of 58% above its accounting book value, likely driven by the intangible value of its gene therapy pipeline. Alternative valuation multiples such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -0.18, suggest that traditional revenue-based valuation models are not applicable, forcing reliance on asset-based or clinical-stage valuation methodologies. The stock has exhibited significant volatility within the past year, trading between a 52-week low of $5.12 and a 52-week high of $20.00, with the current valuation context determined by these historical price extremes. The beta of 1.76 signifies that the stock price is nearly 76% more volatile than the broader market, reflecting the high risk profile associated with speculative biotechnology assets.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient revenue to calculate meaningful growth rates, meaning earnings are not growing faster or slower than revenue because neither metric currently exists. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders but instead retains all cash flows to reinvest into the development of PBFT02 and PBGM01. The overall growth and income profile is characterized by a complete absence of current profitability or dividend distributions, relying entirely on the potential future success of its central nervous system disease treatments to drive future financial expansion.